Breaking News
December 12, 2018 - Sacrificial immune cells alert body to infection
December 12, 2018 - Low-salt diet may be more beneficial for females than males
December 12, 2018 - Major soil organic matter compound battles chronic wasting disease
December 12, 2018 - Findings may open up new ways to treat dwarfism and other ER-stress-related conditions
December 12, 2018 - New computational model provides clearer picture of shape-changing cells’ structure and mechanics
December 12, 2018 - 10 Facts on Patient Safety
December 12, 2018 - Poorest dying nearly 10 years younger than the rich in ‘deeply worrying’ trend for UK
December 12, 2018 - Innovative care model for children with ASD reduces use of behavioral drugs in ED
December 12, 2018 - Spending time in and around Hong Kong’s waters linked to better health and wellbeing
December 12, 2018 - Simple measures to prevent weight gain over Christmas
December 12, 2018 - Research advances offer hope for patient-tailored AML treatment
December 12, 2018 - Researchers discover a ‘blind spot’ in atomic force microscopy
December 12, 2018 - Sprayable gel could help prevent recurrences of cancer after surgery
December 12, 2018 - SLU researchers explore how fetal exposure to inflammation can alter immunity in newborns
December 12, 2018 - How do patients want to discuss symptoms with clinicians?
December 12, 2018 - Zinc chelation may be able to deliver drug to insulin-producing cells
December 12, 2018 - Brigham researchers develop automated, low-cost tool to predict a woman’s ovulation
December 12, 2018 - Some people with Type 2 diabetes may be testing their blood sugar more often than needed
December 12, 2018 - Slow-growing type of glioma may be vulnerable to immunotherapy, suggests study
December 12, 2018 - Study provides new information regarding microRNA function in cellular homeostasis of zebrafish
December 12, 2018 - Study provides new understanding of mysterious ‘hereditary swelling’
December 12, 2018 - Researchers shed new light on how to combat Shiga and ricin toxins
December 12, 2018 - Pregnant Women Commonly Refuse Vaccines
December 12, 2018 - Drug treatment could offer new hope for some patients with brain bleeding
December 12, 2018 - Health care financial burden of animal-related injuries is growing, study says
December 12, 2018 - Macrophage cells could help repair the heart following a heart attack, study finds
December 12, 2018 - Researchers develop new system for efficiently producing human norovirus
December 12, 2018 - New artificial intelligence-based system to differentiate between different types of cancer cells
December 11, 2018 - Brazilian professors propose guidelines for therapeutic use of melatonin
December 11, 2018 - Healthy Lifestyle Lowers Odds of Breast Cancer’s Return
December 11, 2018 - New research identifies two genes linked to serious congenital heart condition
December 11, 2018 - NIH Director talks science, STEM careers with preteens
December 11, 2018 - Disabling a Cellular Antivirus System Could Improve Gene Therapy
December 11, 2018 - New tool swiftly provides accurate measure of patients’ cognitive difficulties
December 11, 2018 - NICE releases new guidelines for diagnosis and management of COPD
December 11, 2018 - Without Obamacare penalty, think it’ll be nice to drop your plan? Better think twice
December 11, 2018 - Researchers capture high-resolution X-ray and NMR image of key immune regulator
December 11, 2018 - Natural flavonoid is effective at treating leishmanisis infections, study shows
December 11, 2018 - Avoidant grievers unconsciously monitor and block mind-wandering contents, study shows
December 11, 2018 - Study identifies how hantaviruses infect lung cells
December 11, 2018 - Improving PTSD care through genetics
December 11, 2018 - Dermatology providers show interest in recommending cannabinoids to patients
December 11, 2018 - Researchers to study effects of electroconvulsive therapy on Alzheimer’s patients with aggression
December 11, 2018 - Four dried fruits have lower glycemic index than starchy foods, study finds
December 11, 2018 - Optimization of drug dose sizes can reduce pharmaceutical wastage
December 11, 2018 - Ultrarestrictive opioid prescribing strategy linked with reduction in number of pills dispensed
December 11, 2018 - PET scans to optimize tuberculosis meningitis treatments and personalize care, study finds
December 11, 2018 - Researchers aim to identify and target high blood pressure indicators
December 11, 2018 - Researchers identify immune cell subset that may drive chronic inflammation
December 11, 2018 - Ezogabine treatment reduces motor neuron excitability in ALS patients, study shows
December 11, 2018 - One implant, two prices. It depends on who’s paying.
December 11, 2018 - Standardizing feeding practices improves growth trends for micro-preemies
December 11, 2018 - COPD Tied to Obesity in Male, Female Never-Smokers
December 11, 2018 - Flossing: Information for Caregivers
December 11, 2018 - Does breastfeeding hormone protect against type 2 diabetes?
December 11, 2018 - Educating future doctors to prescribe physical activity for their patients
December 11, 2018 - Krystal 2000 microplate design improves fluorescence and luminescence measurement
December 11, 2018 - FDA clears mobile medical app to help increase retention in recovery program for opioid use disorder
December 11, 2018 - Overcoming Challenges in High-Speed Centrifugation Experiments
December 11, 2018 - Study shows link between neighborhoods’ socioeconomic status and dietary choices
December 11, 2018 - Lower BMI before obesity surgery predicts greater post-operative weight loss, study finds
December 11, 2018 - Obesity May Be Driving Rise in Uterine Cancers
December 11, 2018 - Antioxidants may prevent cognitive impairment in diabetes
December 11, 2018 - Study discovers link between meditation and how individuals respond to feedback
December 11, 2018 - Researchers identify potential diagnostic tool for Alzheimer’s disease
December 11, 2018 - Oral cancer prognostic signature identified
December 11, 2018 - How Can I Find Out What Caused My Miscarriage?
December 11, 2018 - Novel personalized medicine tool for assessing inherited colorectal cancer syndrome risk developed
December 11, 2018 - Study uncovers 11 new genes associated with epilepsy
December 11, 2018 - Filling research gaps could help develop more disability-inclusive workplaces
December 11, 2018 - Cartilage tissue engineering brings good news for patients with cartilage defects
December 11, 2018 - Novel 3D printing workflow helps predict leaky heart valves
December 11, 2018 - Imagination can help overcome fear and anxiety-related disorders, shows study
December 11, 2018 - Are caries linked to political regime?
December 11, 2018 - Leader in Diabetes Clinical Trials Wins Naomi Berrie Award
December 11, 2018 - Scientists discover cellular mechanism that triggers pneumonia in humans
December 11, 2018 - Increasing mental health problems related to drug use in over 55’s
December 11, 2018 - High-intensity interval exercise could help combat cognitive dysfunction in obese people
December 11, 2018 - Annual flu shot can save lives of heart failure patients
December 11, 2018 - Researchers compare health outcomes for VA and non-VA hospitals
Combo Tx Active in Locally Advanced Pancreatic Ca

Combo Tx Active in Locally Advanced Pancreatic Ca

image_pdfDownload PDFimage_print

Action Points

  • Note that this study was published as an abstract and presented at a conference. These data and conclusions should be considered to be preliminary until published in a peer-reviewed journal.

SAN FRANCISCO — Time to treatment failure in newly diagnosed locally advanced pancreatic cancer exceeded historical standards in patients who received induction therapy with nab-paclitaxel (Abraxane) and gemcitabine, a preliminary trial showed.

The median time to treatment failure (TTF) was 8.8 months compared with the historical duration of 6.6 months. Median progression-free survival approached 1 year, and more than 70% of patients remained alive at 1 year, according to Pascal Hammel, MD, of Hopital Beaujon in Clichy, France, and colleagues.

The findings add to the combination’s activity in pancreatic cancer, following phase III results showing improved survival in association with a significant reduction in tumor burden among patients with metastatic pancreatic cancer, they reported here at the Gastrointestinal Cancers Symposium (GICS).

“The combination of nab-paclitaxel and gemcitabine has promising antitumor activity,” Hammel concluded. “Induction therapy was tolerable and consistent with the known safety profile of the drugs. Quality of life was maintained in most patients. The combination allowed conversion to tumor resection in 16 of 102 patients.”

The single-arm nature of the trial complicated interpretation of the results, said GICS invited discussant Brian M. Wolpin, MD, of Dana-Farber Cancer Institute in Boston. Clinicians can use the results as an aid to patient counseling, and the trial provided data useful for the design and interpretation of future studies.

“These results are unlikely to change clinical practice,” said Wolpin. “Many patients with locally advanced pancreatic cancer already receive multiagent chemotherapy. The study was not designed to definitively demonstrate improvement in patient outcomes. The optimal treatment approach for locally advanced pancreatic cancer remains unclear.”

The rationale for the trial, known as LAPACT, came from recognition that 30% of patients with pancreatic cancer have unresectable locally advanced tumors at diagnosis. Induction chemotherapy is standard for patients in this clinically setting, Hammel noted.

The previously reported success of the combination in patients with metastatic pancreatic cancer suggested potential efficacy of nab-paclitaxel and gemcitabine for locally advanced disease. The National Comprehensive Cancer Network previously gave a qualified recommendation to the combination for locally advanced disease on the basis of the trial in the metastatic setting, Hammel stated.

Investigators in the LAPACT trial enrolled 107 patients with newly diagnosed, locally advanced pancreatic cancer. The patients received a maximum of six cycles of induction therapy with nab-paclitaxel and gemcitabine. Investigators then had the option to continue the combination, treat patients with chemoradiation, or proceed to surgical resection.

All but one patient started induction therapy, and 61 of them completed the planned therapy. Subsequently, 12 patients continued the combination, 17 had chemoradiation, and 16 underwent surgical resection. The remaining 16 did not receive investigator’s choice of treatment after induction.

The protocol-specified standard for time to treatment failure was 6.6 weeks. After follow-up for as long as 24 months, the cohort had a median TTF of 8.8 weeks (90% CI 6.67-9.82).

The induction therapy led to partial response in 35 (32.7%) of 107 patients in the intention-to-treat population. An additional 62 (57.9%) patients had stable disease of at least 16 weeks. The disease control rate (response plus stable disease) was 77.6% if stable disease were defined as ≥16 weeks and 65.4% if defined as ≥24 weeks. Hammel said 38.2% of patients had a reduction in tumor size >30%, most patients had some tumor reduction during induction therapy.

In patients with paired measurements of serum CA19-9, 75.3% had at least a 50% reduction in the cancer antigen, and 56.2% had at least a 70% reduction.

Of the 16 patients who underwent surgical resection after induction therapy, seven had clear surgical margins (R0) and the remaining nine had microscopic residual disease (R1).

The study was supported by Celgene.

Hammel disclosed relevant relationships with Celgene, Shire, Ipsen, and Merck Serono.

2018-01-21T13:30:00-0500

Tagged with:

About author

Related Articles